No profile data available.
Protara Therapeutics, Inc. (TARA) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in New York, United States, with about 28 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$57.44 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $265.09 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Protara Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$265.09 million as of December 4, 2025.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Contineum Therapeutics, Inc. (CTNM), Probi AB (publ) (PBBIF), Bicycle Therapeutics plc (BCYC), ProQR Therapeutics N.v. (PRQR).